The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Sumatriptan injection is indicated in adults for the acute treatment of migraine
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Aims to achieve CDMO sales of US$ 400 million by 2028
The new ECO grade is made using renewable feedstock
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Subscribe To Our Newsletter & Stay Updated
